Agenus Inc. (AGEN)
Agenus Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Agenus Inc. (AGEN) is a Biotechnology company based in US with a market capitalization of $139.1M. Revenue grew 10.4% year-over-year and free cash flow was negative at -$158.9M. This page tracks AGEN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 316 employees · IPO Feb 8, 2000
Valuation
Valuation & price
$3.47as of May 15, 2026· -50.8% vs 52w high
897.6
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$139.1M
Market cap
10.4%
Revenue growth (YoY)
29.6%
Gross margin
-$158.9M
Free cash flow (USD)
$331.9M
Net debt
38.5%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 11, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Agenus Inc.'s market cap?
Agenus Inc. (AGEN) has a market capitalization of $139.1M.
What is AGEN's P/E ratio?
AGEN trades at a price-to-earnings ratio of 897.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
Are insiders buying AGEN stock?
SEC Form 4 filings show no open-market insider buys at Agenus Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.